Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.55USD
1:19pm EDT
Change (% chg)

$-0.11 (-6.63%)
Prev Close
$1.66
Open
$1.60
Day's High
$1.62
Day's Low
$1.55
Volume
3,126
Avg. Vol
14,796
52-wk High
$7.26
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

Aradigm Reports Q4 Loss Per Share Of $0.28
Friday, 23 Mar 2018 08:00am EDT 

March 23 (Reuters) - Aradigm Corp ::ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.28.Q4 REVENUE $2.4 MILLION VERSUS $125,000.AS OF DEC 31, 2017, CO'S CASH AND CASH EQUIVALENTS TOTALED $7.1 MILLION EXPECTED TO BE SUFFICIENT TO FUND OPERATIONS FOR Q1 2018.  Full Article

FDA Declines To Approve Aradigm's Drug Linhaliq
Monday, 29 Jan 2018 07:00am EST 

Jan 29 (Reuters) - Aradigm Corp ::ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA.ARADIGM CORP - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE LINHALIQ NDA IN ITS PRESENT FORM.ARADIGM - FDA'S AREAS OF CONCERN ON LINHALIQ NDA INCLUDE CLINICAL DATA, HUMAN FACTORS VALIDATION STUDY AND PRODUCT QUALITY.ARADIGM - CRL ALSO INCLUDED REQUEST TO CONDUCT ANOTHER HUMAN FACTORS STUDY TO SHOW THAT LINHALIQ PRODUCT PACKAGING & INSTRUCTIONS FOR USE ARE EFFECTIVE.ARADIGM - CRL REQUESTED ADDITIONAL PRODUCT QUALITY INFORMATION WITH RESPECT TO MICROBIOLOGY & A NEW IN VITRO DRUG RELEASE METHOD DEVELOPMENT REPORT.ARADIGM CORP SAYS "WILL REQUEST A MEETING WITH FDA TO DISCUSS TOPICS COVERED IN THE CRL".  Full Article

Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30
Monday, 11 Dec 2017 05:47pm EST 

Dec 11 (Reuters) - Aradigm Corp ::BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING.  Full Article

Aradigm Q3 loss per share $0.26
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Aradigm Corp :Aradigm announces third quarter 2017 financial results.Q3 loss per share $0.26.Aradigm corp - qtrly ‍rev $2.7 million versus $50,000​.  Full Article

Aradigm says FDA accepted NDA for Linhaliq with priority review status
Monday, 25 Sep 2017 07:00am EDT 

Sept 25 (Reuters) - Aradigm Corp :Aradigm announces FDA acceptance of NDA for Linhaliq with priority review status.Aradigm announces FDA acceptance of NDA for Linhaliq with priority review status.Aradigm Corp - ‍PDUFA goal date for completion of FDA review of Linhaliq NDA is January 26, 2018​.  Full Article

Aradigm says Laurence Lytton reports 5.1 pct passive stake in co as of May 31, 2017 - sec filing
Monday, 12 Jun 2017 07:46am EDT 

June 12 (Reuters) - Aradigm Corp :Laurence W.Lytton reports a 5.1 percent passive stake in aradigm corp as of may 31, 2017 - sec filing.  Full Article

Aradigm reports Q1 loss per share of $0.25
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Aradigm Corp :Aradigm announces first quarter 2017 financial results.Q1 loss per share $0.25.Q1 revenue $1.7 million.  Full Article

Aradigm reports Q4 loss per share $0.54
Tuesday, 28 Mar 2017 07:00am EDT 

Aradigm Corp : Aradigm announces fourth quarter 2016 and full year financial results . Q4 loss per share $0.54 . Aradigm Corp - company recorded $125,000 in revenue in Q4 of 2016 compared with $35,000 in revenue in Q4 of 2015 .Aradigm Corp - As of December 31, 2016, company's cash and cash equivalents totaled $22.6 million.  Full Article

Aradigm reports Q2 loss per share $0.59
Wednesday, 10 Aug 2016 07:00am EDT 

Aradigm Corp : Aradigm announces second quarter 2016 financial results . Q2 loss per share $0.59 .Qtrly revenue $14,000 versus $10 million in Q2 of 2015.  Full Article

BRIEF-Aradigm Q1 Loss Per Share $0.32

* Q1 REVENUE $1.5 MILLION VERSUS $1.7 MILLION Source text for Eikon: Further company coverage: